Why the AVT16 filing matters for Alvotech stock

The FDA’s acceptance of Alvotech (ALVO) AVT16 Biologics License Application puts a fresh spotlight on how investors value the company’s growing biosimilar pipeline and recent regulatory progress in immunology.

For AVT16, the proposed interchangeable biosimilar to Entyvio for intravenous use, the key point is substitution. If regulators eventually approve interchangeability, pharmacists in the United States could substitute AVT16 for Entyvio, subject to state pharmacy laws, without needing new prescriptions from prescribers.

That detail matters for investors because ulcerative colitis and Crohn’s disease often require long term treatment, so any interchangeable biosimilar that reaches the market could be directly relevant at the pharmacy counter. AVT16 is still investigational and not yet approved, so the current milestone is about regulatory progress rather than commercial outcomes.

The AVT16 filing and recent BLA resubmissions appear to have coincided with a sharp shift in sentiment, with the share price rallying 19.77% in one day and 31.68% over seven days, even though the year to date share price return is still down 15.20% and the one year total shareholder return has fallen 60.11%. This suggests short term momentum is picking up after a difficult stretch for longer term holders.

If regulatory progress in biosimilars has your attention, it may be a good time to widen your search and check out 39 healthcare AI stocks

With Alvotech stock up 19.77% in a day and 31.68% over seven days, yet still down 60.11% over one year, investors now face a key question: Is this a reset opportunity, or is the market already pricing in future growth?

Most Popular Narrative: 69.3% Undervalued

At a last close of $4.24 versus a narrative fair value of $13.83, the most followed storyline around Alvotech points to a wide gap between price and what long term cash flows could justify, using an 8.73% discount rate.

Ongoing launch and approval pipeline activity, including upcoming regulatory decisions in major global markets (for AVT03, AVT05, AVT23, and others), positions the company to tap into blockbuster biologic markets coming off patent, potentially driving a step change in topline revenue once approvals are secured.

Curious what underpins that big valuation gap? The narrative leans heavily on faster revenue expansion, sharply higher margins and a richer future earnings multiple than many peers. The tension lies in how those three ingredients interact.

Result: Fair Value of $13.83 (UNDERVALUED)

However, investors still need to watch two pressure points closely: execution risk around FDA approvals and milestone timing, and intense biosimilar price competition that could weigh on margins.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Next Steps

Given the mixed signals in the story so far, it makes sense to move fast, check the underlying data yourself and weigh both sides. To see the balance between cautious and optimistic views in one place, review the 3 key rewards and 3 important warning signs

Looking for more investment ideas?

If you stop with just one stock, you risk missing other opportunities that fit your style, so use the screener to line up a broader watchlist.

• Start building a list of potential bargains by checking companies flagged as 47 high quality undervalued stocks that might warrant a deeper look on your watchlist.
• Strengthen your focus on resilience by reviewing stocks highlighted in the 62 resilient stocks with low risk scores so you can quickly spot businesses with lower overall risk profiles.
• Get ahead of the crowd by scanning the screener containing 21 high quality undiscovered gems and see which under-the-radar stocks could deserve a place on your radar.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.